{"celex_id": "31984D0421", "uri": "http://publications.europa.eu/resource/cellar/67de1f00-f87e-4f61-bd31-2b0e2020f208", "type": "Decision", "concepts": ["1445", "1856", "3191", "5034", "5100"], "title": "84/421/EEC: Commission Decision of 23 July 1984 amending Decision 83/494/EEC concerning animal health conditions and veterinary certification for the importation of domestic animals of the bovine and porcine species from Canada\n", "header": "COMMISSION  DECISION\nof 23 July 1984\namending Decision 83/494/EEC concerning animal health conditions and veterinary certification for the importation of domestic animals of the bovine and porcine species from Canada\n(84/421/EEC)\nTHE COMMISSION OF THE EUROPEAN\nCOMMUNITIES", "recitals": ",\nHaving regard to the Treaty establishing the European Economic Community,\nHaving regard to Council Directive 72/462/EEC of 12 December 1972 on health and veterinary inspection problems upon importation of bovine animals and swine and fresh meat from third countries (1), as last amended by Directive 83/91/EEC (2), and in particular Article 8 thereof,\nWhereas Commission Decision 83/494/EEC (3) laid down animal health conditions and veterinary certification for the importation of domestic animals of the bovine and porcine species from Canada;\nWhereas scientific evidence now exists which indicates that the serological test for epizootic haemorrhagic disease requires modification so that results obtained are more specific; whereas, therefore, the test protocol as described in Annex C to Decision 83/494/EEC should be amended;\nWhereas the measures provided for in this Decision are in accordance with the opinion of the Standing Veterinary Commitee,", "main_body": ["The introductory part and point (i) of Annex C.I.5 to Decision 83/494/EEC are hereby replaced by the following:\n'The agar gel immuno-diffusion test shall be carried out according to the following protocol using the New Jersey and Alberta strains of epizootic haemorrhagic disease virus:\n(i) Antigen:\nPrecipitating antigen should be prepared in any cell culture system that supports the rapid multiplication of epizootic haemorrhagic disease virus (New Jersey and Alberta strains). BHK or Vero cells are recommended. Antigen is present in the supernatant fluid at the end of virus growth but requires 50 to 100-fold concentration to be effective. This may be achieved by any standard protein concentration procedure; virus in the antigen may be inactivated by the addition of 0,3 % (v/v) Beta-propiolactone.'", "This Decision shall apply by 1 January 1985 at the latest.", "This Decision is addressed to the Member States."], "attachments": "Done at Brussels, 23 July 1984.\nFor the Commission\nPoul DALSAGER\nMember of the Commission\n(1) OJ No L 302, 31. 12. 1972, p. 28.\n(2) OJ No L 59, 5. 3. 1983, p. 34.\n(3) OJ No L 273, 6. 10. 1983, p. 37."}